Skip to main content
. 2017 May 9;8(40):66975–66986. doi: 10.18632/oncotarget.17756

Figure 8. Summary of the regulation mechanism of miR-138 on suppressing RCC-CSCs.

Figure 8

DAB2IP blocks the binding of DNMT1 and HDAC2 to miR-138 promoter region. This blocking inhibits the methylation of miR-138 promoter, and increased miR-138 expression leads the degradation of ABCA13 and EZH2 which are involved in CSC development. In advanced RCC, loss of DAB2IP allow to the binding of DNMT1 to miR-138 promoter and suppress miR-138.